BCL2 interacting protein 3 pseudogene 11Genealiases: []
Q-omics provides the consensus-scored BNIP3P11 profile across patient tissues and cancer cell-line models. BNIP3P11 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BNIP3P11 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, BNIP3P11 RNA expression shows 17,965 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, BLCA, and ACC as cancer lineages where BNIP3P11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BNIP3P11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BNIP3P11 survival associations across molecular data types. BNIP3P11 RNA expression shows survival associations in the most cancer types (30). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BNIP3P11 RNA expression–survival associations across cancer types. High BNIP3P11 expression shows unfavorable associations in KIRC, ACC, STAD, KIRP, UCEC and KICH. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BNIP3P11 RNA expression.
This table summarizes BNIP3P11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for BNIP3P11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BNIP3P11 shows higher tumor expression in BLCA, LUAD, HNSC, LUSC, STAD and UCEC. The BLCA box plot shows higher BNIP3P11 RNA expression in tumor versus normal tissue (log2 FC = +1.872, t-test p < 0.001).
This table shows molecular features associated with BNIP3P11 in patient tissues and cancer cell lines. In patient samples, BNIP3P11 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
